U.S. FDA panel to review 7 peptides amid growing popularity

U.S. Food and Drug Administration advisers meet this week to evaluate seven popular peptides. The committee will consider whether to allow state-licensed pharmacies to compound these substances for patients with prescriptions. This decision marks a significant moment for the wellness industry, where demand for amino acid chains has grown rapidly.

Peptides such as BPC-157, TB-500, and Semax see frequent use among fitness enthusiasts and biohackers. These substances currently occupy a space between traditional medical clinics and an unregulated grey market. Despite this growth, FDA staff reviewers noted that current data on the safety and efficacy of these compounds remains limited compared to standard pharmaceutical requirements.

Health Secretary Robert F. Kennedy Jr. has publicly supported access to these compounds, suggesting that strict limitations push consumers toward less reliable sources. Conversely, the FDA maintains that the lack of rigorous clinical trials makes widespread approval difficult. The committee decision on adding these substances to the agency's 503A Bulks List remains non-binding, but it sets a tone for future oversight.

Industry participants, including groups like the Alliance for Pharmacy Compounding, advocate for a regulated path. They argue that permitting pharmacy compounding allows for better quality standards and physician supervision. Without this, users often turn to online forums and experimental suppliers. As the meeting proceeds in Maryland, the tension between consumer demand and clinical safety requirements remains the central issue for regulators.